Study summary

Adding epcoritamab to standard pills-and-antibody treatment more than doubled the share of people still in remission

EPCORE FL-1 trial · 488 people, phase 3 · Published December 2025, The Lancet; FDA approved November 2025

What was tested

Epcoritamab, a bispecific antibody that steers the immune system's T cells onto lymphoma cells, added to lenalidomide and rituximab (R2), against R2 alone, for follicular lymphoma that came back after at least one earlier treatment.

What they found

• Estimated progression-free survival at 16 months was 85.5% vs 40.2% (hazard ratio 0.21).
• Response rate was 95% vs 79%.
• Severe side effects were more common (90% vs 68%); cytokine release syndrome was mostly mild and resolved.

What it means

Gives people whose lymphoma returns a chemotherapy-free, fixed-length option that the trial authors call a new standard.